Aurora Cannabis reiterates FY27 Q2 sequential net revenue and adjusted EBITDA growth outlook after Safari Flower deal
AI Market Summary
Aurora Cannabis reaffirmed FY27 Q2 guidance for sequential net revenue and adjusted EBITDA growth, citing incremental contribution from the Safari Flower acquisition following EU-GMP certification and continued strength in Germany and Poland. Ongoing UK expansion via recent acquisitions reinforces a strategy focused on higher-margin international medical cannabis markets. The update signals improving operating momentum and integration progress, which can support risk appetite across smaller, growth-oriented segments.
Impact level
● Low
Affected assets
BTC/USDT-1.08%
AI Insight · BTC/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Aurora Cannabis said it expects sequential growth in fiscal 2027 second-quarter net revenue and adjusted EBITDA. The company said Safari Flower Company, after receiving EU-GMP certification, is expected to add incremental net revenue and adjusted EBITDA. Aurora also cited continued strength in higher-margin international markets, including Germany and Poland, as it targets profitable growth abroad.
